Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study

Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study

BackgroundInterleukin-13 receptor α 2 (IL13Rα2) is a promising tumor-directed antigen of malignant glioma (MG). Here, we examine the efficacy and safety of T cells containing a YYB-103 chimeric antigen receptor (CAR) that can preferentially bind to IL13Rα2 on MG cells.MethodsIL13 was modified on the...

Full description

Bibliographic Details
Main Authors: Kiwan Kim, Ho-Shin Gwak, Nayoung Han, Eun Kyung Hong, Beom K. Choi, Sangeun Lee, Soyoung Choi, Ju-Hwang Park, Ji-Hye Seok, Yeongha Jeon, Hyuntae Cho, Song-Jae Lee, Yura Lee, Ki Taek Nam, Seong-Won Song
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Immunology
Subjects:
chimeric antigen receptor T cell
immunohistochemistry
interleukin-13
malignant glioma
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.715000/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.715000/full

Similar Items